EricJonaschMD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Dr. Jonasch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jonasch's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Eric Jonasch is an oncology specialist based in Houston, TX. He completed his fellowship in Hematology and Medical Oncology at Tufts Medical Center between 1995 and 1998 and graduated from McGill University Faculty of Medicine in 1992. Dr. Jonasch has authored several publications, including recent studies on therapies for renal cell carcinoma and von Hippel-Lindau disease. He is actively involved in clinical trials, notably as the Principal Investigator for studies on immunotherapy strategies and treatments for renal cell carcinoma. He has been recognized as one of America's Top Doctors by Castle Connolly from 2010 to 2025.

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
McGill University Faculty of MedicineClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
PA State Medical License 2019 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2002 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
MA State Medical License 1995 - 2003
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2012-2013

Clinical Trials

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma Start of enrollment: 2005 Feb 01
Completed
Phase 2
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Start of enrollment: 2006 May 01
Terminated
Phase 2
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) Start of enrollment: 2008 Jun 24
Active, not recruiting
Phase 2
Follow-up After Metastasectomy in Patients With Kidney Cancer Start of enrollment: 2009 Jun 09
Active, not recruiting
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer Start of enrollment: 2011 Jan 27
Terminated
Phase 2
TKI 258 in Von Hippel-Lindau Syndrome (VHL) Start of enrollment: 2012 Nov 01
Terminated
Phase 2
Carfilzomib in Refractory Renal Cell Carcinoma (RCC) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer Start of enrollment: 2021 Jan 06
Recruiting
Roles: Contact, Principal Investigator
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC Start of enrollment: 2023 Jun 30
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Data Collection Protocol for Patients With Von Hippel Lindau Disease Start of enrollment: 2023 Aug 24
Recruiting
Roles: Principal Investigator, Contact
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. Start of enrollment: 2023 Feb 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Start of enrollment: 2023 Mar 15
Recruiting
Phase 1, Phase 2
Roles: Contact
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Start of enrollment: 2024 Sep 30
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma.
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Kiran L Malikayil, Devaki Shilpa Surasi
Journal for Immunotherapy of Cancer. 2025-02-12
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.
Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-01-23
1 citations
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Stephanie A Berg, Salvatore La Rosa, Tian Zhang, Phillip M Pierorazio, Laurence Albiges
Urologic Oncology. 2024-11-04

Journal Articles

VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell Carcinoma
Eric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine

Lectures

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Enrichment and Optimization of Anti-VEGF Targeted Strategies in Metastatic Renal Cell Carcinoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Clinical features, diagnosis, and management of von Hippel-Lindau disease
Jonasch E, Plon SE
http://www.uptodate.com/contents/clinical-features-diagnosis-and-management-of-von-hippel-lindau-dis
UpToDate, Wolters Kluwer Health - 2013-02-05
Molecular biology and pathogenesis of von Hippel-Lindau disease
Jonasch E, Plon SE
http://www.uptodate.com/contents/molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease
UpToDate, Wolters Kluwer Health - 2012-06-19
Immunotherapy of renal cell carcinoma
Jonasch E, George D
http://www.uptodate.com/contents/immunotherapy-of-renal-cell-carcinoma
UpToDate, Wolters Kluwer Health - 2012-09-17

Press Mentions

KCA Brings Early-Career Clinicians Together for New Mentorship ProgramNovember 14th, 2024
Clinical Trials for Kidney Cancer: What to KnowDecember 26th, 2022
22 Research Highlights from the Past YearDecember 19th, 2022
Join now to see all